UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period______ from to______ Commission File No. 001-41351 DENALI CAPITAL ACQUISITION CORP. (Exact name of registrant as specified in its charter) | --- | --- | |--------- ...

财务状况 - 公司现金和信托账户中的现金和投资总额为52,072,006美元[19] - 公司当前负债总额为9,206,623美元[20,21] - 公司可赎回普通股为4,537,829股，每股赎回价值11.48美元[22] - 公司将可赎回的A类普通股列为临时权益，并根据赎回价值进行相应调整[91,92,93] - 公司授权发行1,000,000股优先股,截至2024年6月30日未发行[126] - 公司授权发行200,000,000股A类普通股,截至2024年6月30日有4,537,829股可赎回[127] - 公司授权发行20,000,000股B类普通股,截至2024年6月30日有2,062,500股发行在外[128] - B类普通股将在完成首次业务合并时自动转换为A类普通股,转换比例约为20%[130] 经营业绩 - 公司三个月和六个月期间的运营成本分别为168,186美元和536,438美元[26] - 公司三个月和六个月期间的净收益分别为448,912美元和713,242美元[28] - 公司三个月和六个月期间的可赎回普通股每股基本和摊薄净收益分别为0.13美元和0.23美元[29] - 公司三个月和六个月期间的不可赎回普通股每股基本和摊薄净亏损分别为0.05美元和0.12美元[30] - 公司信托账户产生的利息收入在三个月和六个月期间分别为640,157美元和1,294,042美元[27] - 公司三个月和六个月期间的利息费用分别为23,059美元和44,362美元[27] - 公司在2024年6月30日季度获得了来自Sponsor和FutureTech的贷款,使得可转换承兑票据的本金总额分别增加至112.82万美元和127.5万美元[169][170] - 公司在2024年6月30日季度实现净收益44.8912万美元,主要来自信托账户投资收益64.0157万美元[172] - 公司在2024年6月30日半年实现净收益71.3242万美元,主要来自信托账户投资收益129.4042万美元[173] - 公司在2023年6月30日半年实现净亏损55.1393万美元,主要由于运营费用248.5449万美元[175] - 公司在2024年6月30日半年经营活动使用现金48.8664万美元,主要由于信托账户投资收益129.4042万美元[176] - 公司在2023年6月30日半年经营活动使用现金39.8123万美元,主要由于信托账户投资收益193.8505万美元[177] 首次公开募股(IPO)和私募 - 公司于2022年4月11日完成首次公开募股(IPO),共发行8,250,000个单位(含超额配售750,000个单位),每个单位包含一股A类普通股和一份可赎回认股权证[46] - 公司于2022年4月11日同时完成向发起人Denali Capital Global Investments LLC发行510,000个私募单位的交易,募集资金5,100,000美元[46] - 公司于2022年4月11日将IPO及私募单位发行所得净收益84,150,000美元存入信托账户[47] 业务合并 - 公司已与Longevity Biomedical, Inc.签订合并协议,将进行业务合并交易[59][60] - 由于合并协议于2024年6月26日终止,公司将寻求其他方式完成首次业务合并[61][62] - 公司股东于2023年7月10日批准了延长完成首次业务合并的期限至2025年4月11日的提案[63] - 公司已从发起人处获得总计1,275,000美元的可转换借款用于延长合并期限[67][68] - 公司于2024年7月2日宣布与Semnur签订意向书,进行潜在业务合并[148] - 公司于2024年7月10日向保荐人发行了总额最高为18万美元的可转换承兑票据,用于延长业务合并期限[149][162] - 公司于2024年7月10日召开临时股东大会,通过了将业务合并期限从2024年7月11日延长至2025年4月11日的提案,股东赎回了约3,786,000股公众股[150][163] - 公司于2024年7月11日和2024年8月9日分别从保荐人和Scilex处获得15,037美元,用于将业务合并期限延长一个月[151][154] - 公司成立了全资子公司Denali Merger Sub Inc.[167] - 公司合并了全资子公司Longevity Merger Sub和Denali Merger Sub[168] 流动性和持续经营能力 - 公司目前存在流动性和持续经营能力方面的重大不确定性[69][70] - 公司收到纳斯达克发来的通知,连续30个交易日最低上市证券价值(MVLS)低于5000万美元的最低要求,且不符合总资产和总收入均达5000万美元的上市标准[72] - 公司已于2024年7月26日重新符合纳斯达克上市规则,继续在纳斯达克交易[73] - 公司目前的营运资金和借贷能力可能无法满足未来的需求,如果无法筹集到额外资金可能需要采取措施来保持流动性[192] - 公司存在持续经营能力存在重大不确定性的情况,财务报表未包含任何可能因此而需要做出的调整[193] - 公司识别目标公司、进行尽职调查和谈判业务合并的实际成本可能超出预期,可能会导致在业务合并前运营资金不足[194] 其他 - 公司为新兴成长公司,可享受相关豁免,如无需遵守萨班斯-奥克斯利法案404条款的审计要求[77,78] - 公司将现金和投资持有在信托账户,其中自2023年6月4日起全部以活期存款形式持有,年利率约4.5%[81,82] - 公司遵守FASB ASC 260"每股收益"的会计和披露要求[95] - 公司将可赎回和不可赎回普通股的净亏损除

NEW YORK, NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that the Company's shareholders voted in favor of approving amendments to the Company's amended and restated memorandum and articles of association (the "Articles") to extend the date by which the Company must consummate an initial business combination from July 11, 2024 to April 11, 2025 by electing to extend the date to consummate an initial business combination on a monthl ...

NEW YORK, NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the “Company”) announced today that the Company’s shareholders voted in favor of approving amendments to the Company’s amended and restated memorandum and articles of association (the “Articles”) to extend the date by which the Company must consummate an initial business combination from July 11, 2024 to April 11, 2025 by electing to extend the date to consummate an initial business combination on a month ...

Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. (Nasdaq: DECA) (“SPAC”) announce signing of a letter of intent for a proposed business combination, which provides for a pre-transaction equity value of Semnur of up to $2.0 billion, subject to adjustment based on third-party fairness opinion, with expected cash on hand at closing of up to $40 million depending on the number of SPAC shares that are redee ...

Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. (Nasdaq: DECA) (“SPAC”) announce signing of a letter of intent for a proposed business combination, which provides for a pre-transaction equity value of Semnur of up to $2.0 billion, subject to adjustment based on third-party fairness opinion, with expected cash on hand at closing of up to $40 million depending on the number of SPAC shares that are redee ...

NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) ("Denali" or the "Company") announced today that Denali and Longevity Biomedical, Inc. have mutually agreed to terminate their previously announced business combination agreement (the “Business Combination Agreement”).  The Company and its sponsor intend to seek alternative ways to consummate an initial business combination. About Denali Capital Acquisition Corp. Denali Capital Acquisition Corp. is a blank check com ...

NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) ("Denali" or the "Company") announced today that Denali and Longevity Biomedical, Inc. have mutually agreed to terminate their previously announced business combination agreement (the "Business Combination Agreement").  The Company and its sponsor intend to seek alternative ways to consummate an initial business combination. About Denali Capital Acquisition Corp. Denali Capital Acquisition Corp. is a blank check comp ...

NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) ("Denali" or the "Company") announced today that Denali and Longevity Biomedical, Inc. have mutually agreed to terminate their previously announced business combination agreement (the “Business Combination Agreement”).  The Company and its sponsor intend to seek alternative ways to consummate an initial business combination. About Denali Capital Acquisition Corp. Denali Capital Acquisition Corp. is a blank check com ...

NEW YORK, NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) --  Denali Capital Acquisition Corp. (NASDAQ: DECA) (the “Company”) announced today that an aggregate of $50,000 has been deposited into the Company’s trust account to further extend the period of time the Company has to consummate its business combination by an additional month from June 11, 2024 to July 11, 2024 in accordance with the amended terms of the Company’s amended and restated memorandum and articles of association. About the Company Denali Capit ...